{
  "id": "fda_guidance_chunk_0114",
  "title": "Introduction - Part 114",
  "text": "10(1):1–10. Woodcock, J and LM LaVange, 2017, Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both, N Engl J Med, 377(1):62–70. 19 Contains Nonbinding Recommendations APPENDIX Example of a Master Protocol With a Basket Trial Design An example of a master protocol with basket design is the phase 2 trial evaluating vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, as shown in Figure A. Figure A: Vemurafenib in Nonmelanoma Cancers Harboring BRAF V600 Mutations1 * * *NSCLC = Non-small cell lung cancer; ECD = Erdheim-Chester disease; LCH = Langerhans cell histiocytosis. 1Hyman DM, I Puzanov, V Subbiah, JE Faris, I Chau, J-Y Blay, J Wolf, NS Raje, EL Diamond, A Hollebecque, R Gervais, ME Elez-Fernandez, A Italiano, R-D Hofheinz, M Hildago, E Chan, M Schuler, SF Lasserre, M Makrutzki, F Sirzen, ML Veronese, J Tabernero, and J Baselga, 2015, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations, N Engl J Med, 373(8):726–736. 20 Contains Nonbinding Recommendations Example of a Master Protocol With an Umbrella Trial Design An example of a master protocol with an umbrella design is the original version of the LUNGMAP trial, a multidrug, multi-substudy, biomarker-driven trial in patients with advanced/metastatic squamous cell carcinoma of the lung, as shown in Figure B. Figure B: LUNG-MAP Trial in Patients With Squamous Cell Carcinoma of the Lung2 *Archival formalin-fixed, paraffin-embedded tumor, fresh core needle biopsy if needed. NGS = next generation DNA sequencing; OS = overall survival; PFS = progression free survival; TT = targeted therapy; CT = chemotherapy (docetaxel or gemcitabine); TKI = tyrosine kinase inhibitor (erlotinib). 2Herbst RS, DR Gandara, FR Hirsch, MW Redman, M LeBlanc, PC Mack, LH Schwartz, E Vokes, SS Ramalingam, JD Bradley, D Sparks, Y Zhou, C Miwa, VA Miller, R Yelensky, Y Li, JD Allen, EV Sigal, D Wholley, CC Sigman, GM Blumenthal, S Malik, GJ Kelloff, JS Abrams, CD Blanke, and VA Papadimitrakopoulou, 2015, Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, Clin Cancer Res, 21(7):1514–1524. 21 Contains Nonbinding Recommendations Example of a Master Protocol With a Complex Trial Design An example of a master protocol with a complex trial design is the NCI-MATCH trial, as shown in Figure C. Figure C: National Cancer Institute Match Trial Scheme3 * *RECIST = response evaluation",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 151872,
  "end_pos": 153408,
  "tokens": 512,
  "tags": [
    "efficacy",
    "design",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.684Z"
}